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1. Introduction and focus of the present thesis work 
 
This cumulative thesis includes two original first author publications, which focus 
on two mouse models of neuropsychiatric phenotypes. In the first publication we 
developed an autism severity score for mice using Nlgn4 null mutant mice as a 
construct-valid model of heritable monogenic autism (El-Kordi, Winkler et al., 
2013). The second publication describes that Gpm6b deficiency impairs 
sensorimotor gating and modulates the behavioral response to a 5-HT2A/C 
receptor agonist in mice (Dere, Winkler et al. 2014). 
 
1.1 Introduction to neuropsychiatric disorders 
 
Neuropsychiatric disorders are highly heterogeneous with a plethora of symptoms, 
ranging from mild manifestations to severely hampering conditions that interfere 
with everyday life. Classification is difficult, as symptom clusters associated with 
disease entities frequently overlap. Defined diseases are rare and genetic 
components are hard to delineate from symptom complexes (Sullivan et al., 
2012). Even if classification into a distinct disorder is possible, patients with the 
same diagnosis, of schizophrenia for example, are very heterogeneous. Some 
symptoms range from absent to severely abnormal in patients with the same 
diagnosis. It is important to note that psychiatric syndromes are referred to as 
disorders, a term defined as illnesses that disrupt normal functioning. The 
pathophysiology or structural pathology is not known in most cases, therefore use 
of the term ‘disease’ is unsupported (Sullivan et al., 2012). Further studies are 
needed to delineate the molecular pathophysiology of neuropsychiatric disorders 
and facilitate new treatment approaches. 
 
The causes of many neuropsychiatric disorders vary from one disorder to another, 
but in some cases the mechanisms or triggers are unclear. The research focus of 
my work lies on neuropsychiatric phenotypes, mainly associated with autism 
spectrum disorders (ASD) and depression, sharing common features, such as 
increasing prevalence in recent years (Compton et al., 2006; Matson et al., 2011), 
patients with young age (for depression only in some patients), high disease 
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burden, lifelong illness and disturbance of social life. Additionally, treatment 
approaches are limited. There is no specific treatment available to treat the core 
symptoms of ASD (Kumar et al., 2012), while in depression antidepressant 
medications are used to treat certain symptom clusters; however, treatments can 
take several weeks to have an effect (Wong et al., 2004), and such effects are 
seen only in about 50% of depressed patients (Fava, 2003). Further symptoms 
commonly seen in neuropsychiatric disorders (e.g. ASD and depression) include 
lifelong cognitive impairments, hampered development and impeded learning. 
Psychiatric disorders are often accompanied by changes in affective state, which 
are part of the diagnosis; however, lifelong cognitive impairments, which can 
hamper development and learning, are equally cumbering but have been 
comparatively neglected (Millan et al., 2012). Antidepressant drugs, which are 
able to alleviate some symptoms, such as depression and anxiety, often worsen 
or have no effect on the cognitive impairments (Hill et al., 2010). Successful 
treatment of these impairments is not possible without first understanding them, 
which requires further studies (Millan et al., 2012). 
 
Since society is aging (Murray et al., 1997) and number of patients affected by 
neuropsychiatric conditions are increasing (World Health Organization, 2008), 
observation and study of these disorders should become a global health priority 
(Ferrari et al., 2013). Considering the fact that there is so far no cure for most 
neuropsychiatric disorders, one possible target would be improvement of the 
cognitive abilities of psychiatric patients. For this endeavor, there is still need for 
valid animal models that cover a broad variety of symptoms observed in affected 
humans (Cryan & Holmes, 2005). Feasible animal models would facilitate 
pharmacological studies for the development of treatments in this field. In the last 
decade, there has been growing interest in the investigation, modeling and 
treatment of the cognitive dysfunctions involved in neuropsychiatric disorders 




1.2 Animal models of neuropsychiatric conditions with a 
focus on mice 
 
The need for animal models of human disorders has always been present. In the 
past, the rat became the favored rodent for studying behavior, especially for the 
examination of cognitive abilities and behavioral pharmacology. Rats are 
intelligent and more robust when it comes to invasive techniques than smaller 
rodents. Only the development of molecular technologies, which enabled 
researchers to target and alter specific genes in mice (Capecchi, 2005), indirectly 
reduced the impact of rats in the scientific field. Since the successful sequencing 
of the human genome (Venter et al., 2001), the mouse became the second most 
preferred mammal to investigate, due to ease of handling, space- and cost- 
effectiveness and short breeding times. Complete sequencing of the mouse 
genome (Waterston et al., 2002) made it possible to assess target genes for 
neuropsychiatric disorders in knockout mouse models. 
 
To understand neuropsychiatric conditions, complex syndromes must be 
approached by investigation of animal models with the highest validity for the 
relevant symptoms. Furthermore, several models can be used in an additive 
fashion to understand the whole picture (Kalueff et al., 2007). The lack of 
universally accepted animal models for neuropsychiatric disorders has limited the 
development of new pharmacological treatments. Accepting the fact that the 
disorders cannot be modeled by one animal model alone, these single models can 
be used to dissect specific biological features, which can then be targeted by new 




1.3 Introduction to autism spectrum disorders and the Nlgn4 
null mutant mouse model 
 
Autism spectrum disorder (ASD) is an umbrella term for a group of disorders 
sharing common features. They are characterized by symptoms like deficits in 
social interaction, impairments in language acquisition and communication and 
repetitive behaviors, as well as restricted interests (American Psychiatric 
Association, 2013). ASD is of special significance, because it affects brain 
functions that are highly sophisticated: social awareness and communication. It is 
so far incurable, with a high socioeconomic burden and a profound impact on life 
of the patients and their families. 
 
Some individuals with the diagnosis for ASD show mild symptoms, while others 
have more severe symptoms (Murcia et al., 2005), even diminishing their 
everyday functioning and quality of life. The wide range of observed symptoms is 
referred to when describing any of such disorders as ‘Autism Spectrum Disorder’ 
(Persico et al., 2006). 
 
As defined in the Diagnostic and Statistical Manual of Mental Disorders 4th edition 
(DSM-IV), observation of a total of six items, composed of two items of qualitative 
impairment in social interaction, at least one item of qualitative impairment of 
social communication, and one item of restricted repetitive and stereotyped 
pattern, justifies the diagnosis of an autistic disorder (American Psychiatric 
Association, 2000).  
 
It has been observed that autistic individuals can additionally show a range of 
symptom features, which diverge from the typical symptomatic picture for ASD. 
For example, Courchesne and coworkers found an increase in brain volume in the 
frontal lobes and the anterior temporal regions in ASD patients (Courchesne et al., 
2007). Other examples of atypical symptoms include disturbed sensory 
responsiveness, abnormal motor activity, disrupted sleep and associated seizures 
(Lord et al., 2000; Newschaffer et al., 2007). The characteristics of these patients 
are grouped under the label of ‘Pervasive Developmental Disorders’. The 
complexity of the heterogeneity becomes even more obvious when one considers 
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the latest version of the Diagnostic and Statistical Manual of Mental Disorders V 
(American Psychiatric Association, 2013) in which the definition of autism has 
been changed. With this iteration of the DSM, the category of ASD has officially 
been recognized. This umbrella term now replaces the group of ‘Pervasive 
Developmental Disorders’, including ‘Autistic Disorders’, ‘Asperger’s Disorders’ 
and ‘Pervasive Developmental Disorder not otherwise specified (including atypical 
autism)’. Changes to diagnostic criteria are still under consideration, pending new 
advances in understanding this disorder, indicating that autism is not a single 
disease entity, but rather shows a combination of clinical symptoms.  
 
In 2008 the overall estimated prevalence of ASD was 11.3 per 1,000 American 
children at the age of eight year (Baio, 2012). However, sex dependence is clear 
as boys are roughly four times more often affected than girls (estimated 
prevalence from 2008: 18.4 per 1,000 in males, 4.0 per 1,000 in females) (Baio, 
2012). In the last years, the prevalence of autism has increased for unknown 
reasons. This increase could be partially explained by the increased awareness of 
the disease (Rice, 2011). Diagnosis is purely based on the examination of patients 
and their behavior, since there are no biomarkers or parameters available to verify 
the disease type or state (Voineagu et al., 2013). As such, diagnosis numbers and 
types can vary substantially, strongly dependent on observer knowledge and 
training (Matson et al., 2011). In particular, cognitive symptoms might be judged 
subjectively when results of examinations are not easily categorized, especially in 
nonverbal and young children (Manning-Courtney et al., 2013). 
 
In the case of monozygotic twins, concordance rates vary from 60-95%, indicating 
a robust genetic component of the disorder (Murcia et al., 2005). Different 
screening methods and diagnostic criteria lead to a wider range of estimates in 
heritability (Murcia et al., 2005). Although heritability is high in monozygotic twins, 
indicating the genetic contribution, finding the causative mutations or aberrations 
is not straightforward. Epidemiological studies have attempted to find a genetic 
basis for ASD resulting in a plethora of candidate genes probably involved in the 
development of the disease (Risch et al., 1999). However, the inheritance of ASD 
is far more complex than basic Mendelian genetics, suggesting contributions from 
multiple genes and from external factors, such as the environment (e.g. Gadad et 
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al., 2013). In some cases, single gene mutations have been linked to ASD; 
however, these genes are interestingly always synaptic genes and it is therefore 
unsurprising that abnormal synaptic homeostasis has been suggested as a risk 
factor for ASD (Bourgeron, 2009).  
 
Though the etiology of ASD remains unknown, some monogenic heritable forms 
have been observed, a number of which were found to be linked to genes on the 
X-chromosome (for review see Provenzano et al., 2012). Of these, the most 
important and relevant for ASD are the Fragile Mental Retardation locus, the 
methyl-CpG binding protein 2 locus, the TSC locus, and the loci encoding NLGN3, 
NLGN4, NRXN1, SHANK2 and SHANK3. 
 
Alteration of the X-linked Fragile Mental Retardation locus (FMR1) leads to Fragile 
X Syndrome, which is characterized by mental retardation and autistic features. 
Fmr1 knockout mice show increased activity and attention dysfunctions, though 
the results of social tests vary and require further investigation (Mineur et al., 
2002; for review see Bernardet et al., 2006). 
 
Mutations in the gene encoding methyl-CpG binding protein 2 (MECP2) lead to 
Rett Syndrome (RTT), an X-linked developmental disorder. Mouse models with 
dysfunctional MeCp2 show symptoms similar to RTT (Chen et al., 2001) and 
exhibit enhanced anxiety and disturbed social interaction (Chahrour et al., 2007). 
Tuberous sclerosis is a genetic disease showing some symptoms reminiscent of 
ASD. The proteins TSC1 and TSC2 inhibit the mammalian target of rampamycin 
(mTOR) in the phosphoinositide 3-kinase (PI3K) signalling pathway (Yates, 2006).  
 
Loss-of-function mutations in the genes of NLGN3, NLGN4 (Jamain et al., 2003), 
NRXN1 (Etherton et al., 2009), SHANK2 (Berkel et al., 2010) or SHANK3 (Durand 
et al., 2007) have been perceived to cause monogenic heritable forms of ASDs, 
as well as point mutations of neuroligin-3 (homolog of neuroligin-4). NL-3 deficient 
mice show reduced ultrasound vocalizations and a lack of preference for social 
novelty (Radyushkin et al., 2009). NRXN1, SHANK2 and SHANK3, though 
important for ASD, lie outside the scope of this thesis and will therefore not be 
further discussed.  
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In humans there are five Neuroligin (NL) isoforms: NL1-3, NL4X and NL4Y 
(Jamain et al., 2003). The distribution of the proteins is not limited to one specific 
brain area, they are essentially expressed all over the central nervous system, 
with NL4 being consistently localized to glycinergic postsynapses in the brainstem 
and spinal cord of mice (Hoon et al., 2011). 
 
Altered synaptic gene expression can therefore be directly associated with autism 
spectrum disorders, indicating that synaptic integrity is of great importance for 
mental health, especially during early brain development (Currenti, 2010). 
Disruption of proteins involved in the regulation of synaptic protein synthesis can 
lead to aberrant transduction signaling in affected patients (Jamain et al., 2003). 
These familial monogenic heritable forms of autism could therefore be a possible 
basis for studying ASD and have led to the development of animal models with a 
nonsyndromic character.  
 
Based on the fact that the criteria for autism diagnoses are purely based on 
behavior, it is important to consider that a valid animal model should cover the 
three main symptom clusters (Crawley, 2012). Most animal models for ASD show 
and are limited to face validity, because they model only the characteristic human 
symptoms. Recent animal models additionally show construct validity, by 
presenting also the underlying mechanism (e.g. animals modeling monogenic 
heritable forms of autism). Optimal animal models would simultaneously fulfill 
predictive validity; however, since there is no effective treatment available for 
autism (Kumar et al., 2012), it is not currently possible to test the predictive 
validity.  
 
Animal models that are able to solidly model facets of the disease should replicate 
a subset of the reported pathologies (Murcia et al., 2005). ASD affects the social 
and communicative functioning of patients, some features of which are difficult to 
replicate in a rodent model of this disorder. To meet the criteria of being an actual 
animal model for ASD, the model has to cover the three main features of the 
disorder: social interaction deficits, communication deficits and restricted, 
repetitive and stereotyped patterns of behavior (Crawley, 2012). In former times, 
experimentally induced abnormalities produced behavioral changes reminiscent of 
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autistic characteristics. Lesion studies of the amygdala pointed to 
behavioral abnormalities that could be studied (Daenen et al., 2002); however, 
these changes were not based on genetic abnormalities or aberrant 
developmental pathways. Infectious agents and chemicals were also used to 
induce alterations in the global brain (Murcia et al., 2005). 
 
ASD has been recognized as a comorbid feature of more than a hundred genetic 
and genomic disorders (Betancur, 2011). However, ASD mutations with high 
penetrance are rare, like the Rett’s syndrome mutations in MECP2. Estimates 
from exonic de novo mutations suggest that ASD is highly polygenic (Sanders et 
al., 2011), particularly involving synaptic regions, which supports the previously 
mentioned hypothesis.   
15 
1.4 Introduction to depression and the Gpm6b null mutant 
mouse model 
 
According to the World Health Organization, depression (short for major 
depressive disorder) will be the second leading cause of disability by 2020 
(Murray et al., 1997) and is associated with a high risk for suicide (Lesage et al., 
1994). Suicides are the second leading cause of death among young people 
between the age of 15-24 and 25-34 (Heron, 2013), indicating a global health 
priority for depressive disorders (Ferrari et al., 2013). The World Health 
Organization is classifying severe depression as a “severe” disability (equivalent 
level to blindness, Down syndrome or active psychosis), which accounted for one 
third of all disabilities worldwide in 2008 (World Health Organization, 2008). The 
financial burden for the society is immensely high, estimated at, for example $83.1 
billion for the year 2000 in the United States (Greenberg et al., 2003). 
 
The pathophysiology of depression is still not completely understood; however 
there are several mechanisms possibly involved (Femenia et al., 2012). In a great 
number of studies, it has been shown that there is a robust link between the short 
form of the serotonin transporter (SERT) polymorphism and depression (for 
review see Sharpley et al., 2014). In 1996 it was revealed that reduced SERT 
expression and altered SERT function (due to a repeat length variation in the 
SERT gene SLC6A4) are associated with anxiety and depression-related 
personality traits (Lesch et al., 1996). SERT actively transports serotonin from the 
synaptic cleft into the presynaptic neuron and it has been shown that M6b 
interacts with this transporter (Fjorback et al., 2009). The interaction between M6b 
and SERT has been hypothesized to mediate a down-regulation of SERT uptake, 
and could therefore be part of the regulatory mechanism of SERT trafficking 
(Fjorback et al., 2009). Alterations in SERT mediated serotonin reuptake and the 
accompanying effects on serotonergic neurotransmission have also been linked to 
psychiatric disorders (Murphy et al., 2004). Mouse models of altered SERT 
function have yielded observations of phenotypic changes including increased 
anxiety and stress-related behaviors (for review see Murphy et al., 2008).  
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M6A (Gpm6a) and M6B (Gpm6b) belong to a proteolipid family of neuronal 
tetraspan glycoproteins, which are expressed throughout the brain (Werner et al., 
2001) and (Möbius et al., 2008). M6b was first described when Yan and 
coworkers utilized expression cloning to determine the sequence of M6 and its 
functional role. They found two cDNAs, which show a high homology to the 
oligodendroglial proteolipid protein PLP (Yan et al., 1993), which is a structural 
protein of the central nervous system (CNS) myelin (Möbius et al., 2008). 
Mutations in PLP have been linked to Pelizaeus-Merzbacher disease and spastic 
paraplegia type 2 (Saugier-Veber et al., 1994), indicating an important role of this 
protelipid family in health and disease.  
 
More than 80 mutant animal models related to depression and anxiety have been 
described to date (Cryan & Holmes, 2005). In 1969, McKinney and Bunney 
suggested that the minimal requirements for the validity of an animal model for 
depression are: 
- ‘reasonably’ analogous to the symptomatology of the disorder; 
- behavioral changes can be objectively monitored; 
- behavioral changes are reversed by the same pharmacological treatments 
as in humans; and 
- reproducibility in different laboratory settings (McKinney et al., 1969).  
This standard built the basis for today’s judgement of animal model validity. 
According to these standards, we tested Gpm6b deficient mice in a number of 
paradigms, all important for the examination of depressive phenotypes. Since 
depression is often viewed as a manifestation of a disturbed reaction to stressful 
life events, behavioral paradigms have to account for stress. As such, the 
behavioral readouts of the depression assessment in rodents include exposure to 
stressful situations. One example of these experimental evaluations is the forced 
swim test (FST) for behavioral despair in mice, introduced by Porsolt in 1977 
(Porsolt et al., 1977). A similar test is the tail suspension test (TST), in which mice 
are hung by their tails (Chermat et al., 1986; Cryan, Mombereau, et al., 2005). 
Both tests involve mice struggling to escape, however in both cases the mice will 
not be able to succeed. The time interval during which the mice keep exhibiting 
escape movements is measured, providing a feasible indicator for individual 
willingness to survive or surrender, making this test a very efficient tool for 
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depression like symptoms in mice and therefore the screening of new 
antidepressant drugs (Cryan & Holmes, 2005). Anhedonia, which is another 
important diagnostic criterion for depression, can be measured by sucrose 
preference in mice. Already in 1987 it was shown in rats, that stress induces 
anhedonia, which can be reversed by antidepressant treatment (Willner et al., 
1987).  
 
In my second project, we characterized a mouse lacking Gpm6b, to assess the 
impact of this deficiency on the behavioral phenotype of Gpm6b deficient mice 
and its impact on SERT signaling. Since it is well known that impairments in 
serotonin neurotransmission are involved in the symptoms associated with major 
depressive disorder, we studied in a series of experiments, whether Gpm6b-
deficient mice (that might suffer from a lack of extracellular serotonin due to an 
increase in the cell-surface expression of the serotonin transporter) would 
consequently exhibit depression-like symptoms along with cognitive impairments 




2. Aims of the present thesis work 
 
The projects of my PhD thesis were mainly stimulated by the growing interest in 
animal models of neuropsychiatric diseases, such as autism-spectrum disorders, 
major depression, anxiety disorders and schizophrenia. Since valid animal models 
are needed for the assessment of higher brain functions and their variance, the 
present thesis work aims to investigate two models, one for ASD and one for 
depression. 
 
2.1 Aim of Project 1 
 
In this project, we specifically wanted to address autistic behavior in a construct 
valid animal model for ASD (Nlgn4 knockout), extending previous findings (Jamain 
et al., 2008) to the extensive assessment of repetitive stereotypic behavior, and 
additionally to the female gender. Furthermore, we wanted to use the test 
readouts to generate an autism composite score, which would allow a sharp 
discrimination between non-autistic and autistic animals. This discrimination is 
crucial for the development of future therapeutics as well as treatment strategies 
and can therefore not be overestimated. 
 
2.2 Aim of Project 2 
 
In my second project, we wanted to explore the use of Gpm6b deficient mice as 
an animal model of depression. To pursue this question, we were interested in the 
assessment of the basic behavioral phenotype of Gpm6b deficient mice, since 
there was no information available at that time. We were specifically interested in 
the behavioral domains of sensory functions, motor functions, exploratory 
behavior, sociality, cognition and readouts for depression. Moreover, we wanted 
to reveal potential changes in 5-HT neurotransmission in the brain of Gpm6b 
deficient mice by using a 5-HT2A/C receptor agonist and comparing behavioral 
responses, between knockout and wildtype littermates.  
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3. Development of an autism severity score for mice 
using Nlgn4 null mutants as a construct-valid model 
of heritable monogenic autism 
3.1 Overview of project 1 
 
The term “Autism Spectrum Disorder” (ASD) is summarizing a group of pervasive 
developmental disorders characterized by difficulties in social interaction, 
communication and by the expression of stereotyped repetitive behaviors and 
restricted interests (American Psychiatric Association, 2013). Symptoms can vary 
from mild to very severe occurrence. The etiology of ASD is still unknown in most 
cases, but monogenic heritable forms exist that have provided insight into ASD 
pathogenesis and have led to the notion of autism as a ‘synapse disorder’ (El-
Kordi et al., 2013). Several of these monogenic heritable ASD forms are caused 
by loss-of-function mutations in the NLGN3, NLGN4, NRXN1, or SHANK2 and 
SHANK3 genes. The gene NLGN4 encodes Neuroligin-4 (NL4), which is a cell 
adhesion protein at nerve cell synapses, and the current state of research 
indicates that aberrant signalling between nerve cells causes the ASD phenotype 
in affected patients (Jamain et al., 2003). Our group was able to show that Nlgn4 
null mutant (Nlgn4 -/-) mice exhibit autistic-like behavior, including disturbed social 
interaction and compromised ultrasound vocalization. Therefore these animals 
can be used as a genetic animal model for ASD, due to their construct and face 
validity (Jamain et al., 2008). 
 
The number of valid animal models for autism is still limited, and so far little is 
known about sex differences in these animal models (for review, see Kokras et al., 
2014). Therefore, in my project, we wanted to extend the characterization of Nlgn4 
null mutant mice from males to females in order to delineate fine sex differences. 
Additionally, we included a more comprehensive set of ASD relevant readouts, 
especially extending to repetitive stereotyped behaviors. 
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For this project, we used male and female Nlgn4 null mutant mice and their 
wildtype littermates. The animals underwent basic behavioral characterization 
including elevated plus maze, open field, hole board, rota-rod and prepulse 
inhibition of the startle response to measure general activity, anxiety levels, motor 
performance, exploratory behavior and sensorimotor gating, respectively. The 
resulting findings show that the basic behavior is not affected in Nlgn4 null mutant 
mice. However, we found significant differences in Nlgn4 null mutant social 
behavior and communication compared to wildtype animals in both genders. 
Social interaction time was significantly decreased in both male and female Nlgn4 
null mutants (see Fig. 1 in the publication). In terms of vocalization, the numbers 
of calls were significantly reduced in both genders, compared to their wildtype 
littermates. We additionally addressed nest-building abilities in these animals, 
however only the male Nlgn4 null mutant mice showed significantly reduced nest-
building scores. Female mice showed the same tendency, but their performance 
did not reach statistical significance compared to wildtype females.  
 
The results of all tests relevant for ASD showed that Nlgn4 null mutant mice of 
both genders exhibit a syndrome covering the three main domains: disturbed 
social interaction, compromised communication and expression of repetitive 
behaviors. From the results of the behavioral tests, we were able to derive an 
autism severity composite score, composed of seven autism-relevant behavioral 
readouts for mice, as an indicator of overall syndrome severity. With this score, 
we are able to predict the genotype with a 100% accuracy in males and with an 
accuracy of 83% in females. The development of the autism composite score in 
Nlgn4 null mutant mice has helped to alleviate the variance in observed behaviors 
in mice and might therefore be an important tool for the evaluation of new 
pharmacological treatment approaches targeting NLGN4 function (El-Kordi et al., 
2013; Wöhr et al., 2013). Although there is a huge variety of symptoms caused by 
varying expression levels of a single gene, there would optimally be one treatment 
for all the symptoms caused by a particular genetic modification. The autism score 
has already been recognized and appreciated in the field, and may help to 
establish a “one mutation - one drug” approach (Wöhr et al., 2013). 
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3.2 Original publication 
 
El-Kordi A1, Winkler D1, Hammerschmidt K, Kästner A, Krueger D, Ronnenberg A, 
Ritter C, Jatho J, Radyushkin K, Bourgeron T, Fischer J, Brose N, Ehrenreich H: 
Development of an autism severity score for mice using Nlgn4 null mutants as a 
construct-valid model of heritable monogenic autism. Behavioral Brain Research 
2013; 251(8):41-9. 
 
1Equal contribution  
 
Own contribution: I was responsible for planning and conducting the behavioral 
experiments of this study (elevated plus maze, open field, hole board, rotarod, 
prepulse inhibition, social interaction, LABORAS), including the establishment of a 
new grooming test (according to Kalueff et al. Nature Protocols 2007) in our 
facility. Together with Ahmed El-Kordi, I analyzed the data statistically, interpreted 
the findings and generated the graphical illustrations of the data (Figures 1 and 2) 
that were used for this publication. Furthermore, I was involved in the design, 






































4. Gpm6b deficiency impairs sensorimotor gating and 
modulates the behavioral response to a 5-HT2A/C 
receptor agonist 
4.1 Overview of project 2 
 
Depression (major depressive disorder) is the leading cause of disability 
worldwide (Ferrari et al., 2013) and is associated with a high risk for suicide 
(Lesage et al., 1994). Suicides are the second leading cause of death among 
young people between the age of 15-24 and 25-34 (Heron, 2013), indicating a 
global health priority for depressive disorders (Ferrari et al., 2013).  
 
The pathophysiology of depression is still not completely understood, though 
several mechanisms are possibly involved (Femenia et al., 2012). In a great 
number of studies, it has been shown that there is a robust link between the short 
form of the serotonin transporter polymorphism and depression (for review see 
Sharpley et al., 2014). The serotonin transporter (SERT) actively transports 
serotonin from the synaptic cleft in the presynaptic neuron and it has been shown 
that M6b interacts with this transporter (Fjorback et al., 2009). In my second 
project, we addressed a mouse model deficient of Gpm6b, to assess the impact of 
this deficiency on the behavioral phenotype and on SERT signaling. 
 
To elucidate the role of Gpm6b on behavior, we used Gpm6b null mutant 
(Gpm6b-/-) male and female mice. A comprehensive battery of behavioral 
approaches was utilized to test for sensory and motor functions, cognition, social 
behavior, as well as anxiety. Gpm6b null mutant mice displayed completely 
normal basic behavior, indistinguishable from their wildtype littermates. Only the 
home-cage observation with LABORAS indicated a slightly increased locomotion 
(indicated by greater distance travelled) and therefore reduced immobility (time) in 
male Gpm6b null mutant mice compared to their wildtype littermates. From our 
data, one can also derive a general sex difference, regardless of the genotype. 
This is of importance due to the recent increase in interest in sex differences 
among animal models for psychiatric conditions (Kokras et al., 2014) and the sex 
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differences observed in humans under neuropsychiatric conditions, e.g. females 
have a higher lifetime prevalence of depression (Rafful et al., 2012). 
 
As mentioned above, impairments in serotonin neurotransmission are involved in 
the symptoms associated with major depressive disorder. Therefore, in another 
series of experiments, we wondered whether Gpm6b-deficient mice (that might 
suffer from a lack of extracellular serotonin due to an increase in the cell-surface 
expression of the serotonin transporter) would consequently exhibit depression-
like symptoms along with cognitive impairments. Although we suspected a 
depressive phenotype in Gpm6b null mutant mice, we found all our tests for 
depression unaffected. The results of the forced swim test, tail suspension, 
sucrose preference and the chimney test were comparable between the Gpm6b 
null mutant mice of both genders and their wildtype littermates. 
 
Cognitive performance was assessed with novel object recognition and Morris 
water maze. Neither immediate, nor delayed object recognition yielded a 
difference in performance by genotype. The spatial learning task, as well as its 
reversal (as a measure of cognitive flexibility), remained unaffected by the Gpm6b 
deficiency in mice. 
 
In the prepulse inhibition paradigm (PPI) we were able to explore the impact of 
Gpm6b-deficiency on sensorimotor gating, which resulted in a decreased 
response compared to wildtype animals.  
 
In the brains of suicide completers, the mRNA levels of GPM6B were found to be 
reduced. As a result we assessed the behavioral response of Gpm6b null mutant 
mice to DOI (5-HT2A/C receptor agonist). Our data indicated impaired receptor 
signalling as an effect of the absence of Gpm6b, leading to a blunted behavioral 





4.2 Original publication  
 
Dere E1, Winkler D1, Ritter C, Ronnenberg A, Poggi G, Patzig J, Gernert M, Müller 
C, Nave KA, Ehrenreich H, Werner HB: Gpm6b deficiency impairs sensorimotor 
gating and modulates the behavioral response to a 5-HT2A/C receptor agonist. 




Own contribution: I was responsible for conducting the behavioral experiments 
(elevated plus maze, open field, rota-rod, hole board, social interaction, marble 
burying, novel object recognition and LABORAS). Together with Ekrem Dere, I 
analyzed and discussed the data and designed the graphs and figures 
implemented in the publication. Furthermore, I was involved in the design, writing, 
























5.  Summary and conclusions 
 
In this cumulative thesis, two original first author publications have been included 
with the focus on two mouse models of neuropsychiatric phenotypes. In the first 
publication we created and refined an autism severity score for mice using Nlgn4 
null mutant mice as a construct-valid model of heritable monogenic autism (El-
Kordi A, Winkler D et. al 2013). The second publication describes that Gpm6b 
deficiency impairs sensorimotor gating and modulates the behavioral response to 
a 5-HT2A/C receptor agonist in mice (Dere E, Winkler D et al. 2014). 
 
5.1 Development of an autism severity score for mice using 
Nlgn4 null mutants as a construct-valid model of heritable 
monogenic autism 
 
Autism spectrum disorder (ASD) is characterized by symptoms such as difficulties 
in social interaction, disturbed communication, and expression of stereotyped 
repetitive behaviors and restricted interests. Among patients, symptoms can vary 
noticeably from mild to very severe presentation. From this highly heterogeneous 
picture, conclusions about the origin of the disorder or possible genes involved are 
difficult to draw. In the last years the number of individuals receiving the diagnosis 
of autism spectrum disorder has increased for unknown reasons, though 
increased awareness may have played a role, since diagnosis depends entirely 
on observation and identification of unusual behavior in patients. Prevalence rates 
of the disorder continue to rise, indicating that fine-tuning of diagnosis methods is 
still necessary, as well as studying the molecular basis and influencing factors 
(e.g. environmental) of the disease. The interaction of multiple factors affecting the 
prevalence of ASD is still not fully understood and requires further investigation 
(Baio, 2012). 
 
Since the etiology of ASD is still unknown in most cases, one possibility is to focus 
on the monogenic heritable forms that have been described, which are caused by 
loss-of-function mutations in synaptic genes. Aberrant signalling between nerve 
cells caused by mutations in NLGN4, results in the ASD phenotype in affected 
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patients (Jamain et al., 2003). Previously, our group was able to show that Nlgn4 
null mutant (Nlgn4 -/-) mice exhibit autistic-like behavior, including disturbed social 
interaction and compromised ultrasonic vocalization. As such, these animals can 
be used as construct and face valid genetic animal model for ASD (Jamain et al., 
2008). Since so far little is known about sex differences in these animal models 
(for review see Kokras et al., 2014), we extended the characterization of Nlgn4 
null mutant mice from males to females in order to delineate acute sex 
differences. Additionally, we included a more comprehensive set of ASD relevant 
readouts, especially extending to repetitive stereotyped behaviors. Male and 
female Nlgn4 null mutant mice and their wildtype littermates underwent basic 
behavioral characterization including elevated plus maze, open field, hole board, 
rota-rod and prepulse inhibition of the startle response. The resulting findings 
show that the Nlgn4 null mutant mice exhibit normal basic behavior. By examining 
ASD relevant readouts, we noticed significant differences in Nlgn4 null mutant 
social behavior and communication compared to wildtype animals and both 
genders were affected. Although we were able to show the autistic phenotype in 
both genders, the results indicated a marginally milder phenotype in females with 
a mild deviant phenotype.  
 
Our results align with the fact that human patients with the same mutation can 
show a different combination of symptoms with differing severities, and indicate 
that environmental influences or epigenetic modifications may be involved, 
although our animals were kept in a stable environment with defined housing 
conditions. The importance of the environment, namely the housing conditions, 
was clearly illustrated by the results of the marble burying test. In our experience, 
group housing mitigated the compulsive phenotype. Further work is needed to 
delineate the effects of environmental changes. 
 
From the results of the behavioral tests, we were able to derive an autism severity 
composite score, as an indicator of overall syndrome severity. With this score, we 
are able to predict the genotype with a 100% accuracy in males and with an 
accuracy of 83% in females. The development of the autism composite score in 
Nlgn4 null mutant mice has helped to limit the variance in observed behaviors in 
the mice, and could therefore be an important tool for the evaluation of new 
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pharmacological treatment approaches targeting NLGN4 function (El-Kordi et al., 
2013; Wöhr et al., 2013). Although there is a huge variety of symptoms caused by 
varying expression levels of a single gene, there would optimally be one treatment 
for all the symptoms caused by a particular genetic modification.  
 
Possibly, there are different mechanisms involved in the development of ASD, 
finally leading to the identification of various forms of ASD, which than would lead 
to a further refinement of diagnostic criteria. Some progress in identification of 
susceptibility genes is ongoing, while refinement of imaging techniques continues 
to improve definition rates of structural correlates and abnormalities in autism.  
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5.2 Gpm6b deficiency impairs sensorimotor gating and 
modulates the behavioral response to a 5-HT2A/C 
receptor agonist 
 
Depression (major depressive disorder) is the leading cause of disability 
worldwide (Ferrari et al., 2013) and is associated with a high risk of suicide 
(Lesage et al., 1994), indicating a global health priority for depressive disorders 
(Ferrari et al., 2013). The pathophysiology of depression is still not completely 
understood, though there are several mechanisms possibly involved (Femenia et 
al., 2012). A number of studies show possible involvement of the serotonin 
transporter and disturbed serotonergic signaling in the emergence of depression 
(for review see Sharpley et al., 2014). The serotonin transporter (SERT) actively 
transports serotonin from the synaptic cleft in the presynaptic neuron, and M6b 
has been shown to interact with this transporter (Fjorback et al., 2009). In my 
second project, we addressed a Gpm6b deficient mouse model, to assess the 
impact of this deficiency on the behavioral phenotype of Gpm6b deficient mice 
and on SERT signaling; in order to obtain insight into the development of 
depressive phenotypes.  
 
To elucidate the role of Gpm6b on behavior, we used Gpm6b null mutant 
(Gpm6b-/-) male and female mice and assessed motor functions, cognition, social 
behavior, as well as anxiety, and found Gpm6b null mutants indistinguishable from 
their wildtype littermates. However, a general sex difference was observed, 
independent of the genotype. Such sex differences have already been described 
among other animal models for psychiatric conditions (Kokras et al., 2014). 
 
As mentioned above, impairments in serotonin neurotransmission are involved in 
the symptoms associated with major depressive disorder. Therefore, in another 
series of experiments, we wondered whether Gpm6b-deficient mice (that might 
suffer from a lack of extracellular serotonin due to an increase in the cell-surface 
expression of the serotonin transporter) would consequently exhibit depression-
like symptoms along with cognitive impairments. Although we suspected a 
depressive phenotype in Gpm6b null mutant mice, we found all of our tests for 
depression unaffected. The results of the forced swim test, tail suspension, 
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sucrose preference and the chimney test were comparable between the Gpm6b 
null mutant mice of both genders and their wildtype littermates. Depression may 
have several forms (e.g. psychotic depression or melancholia) (Parker, 2005), and 
since the domains affected in depression are difficult to model in rodents, further 
work is needed to find animal models with high face, construct and predictive 
validity. 
 
Cognitive performance was assessed with novel object recognition and Morris 
water maze. Neither immediate, nor delayed object recognition yielded to a 
difference in performance by genotype. The spatial learning, as well as its reversal 
(as a measure of cognitive flexibility), remained unaffected by the Gpm6b 
deficiency in mice, compared to their wildtype littermates.  
 
In the prepulse inhibition (PPI) paradigm we were able to explore the impact of 
Gpm6b-deficiency on sensorimotor gating, which resulted in a decreased 
inhibition response of the sensory information compared to wildtype animals. This 
finding is coherent with the literature, since it was shown that severe depletion of 
brain serotonin leads to disrupted PPI of the acoustic startle response (Fletcher et 
al., 2001).  
 
In the brains of suicide completers, mRNA levels of GPM6B were found to be 
reduced. Therefore we assessed the behavioral response of Gpm6b null mutant 
mice to DOI (5-HT2A/C receptor agonist). Our results indicated impaired receptor 
signalling as an effect of the absence of Gpm6b, leading to a blunted behavioral 
response to the 5-HT2A/C receptor agonist. 
 
It has been noted recently that the test order can influence the results of specific 
tests (McIlwain et al., 2001). Ideally, for every test a new group of animals should 
be used; however, this is not possible according to animal welfare regulations and 
therefore it is possible that this effect led to the disappearance of the depressive 






Finding a way to model complex human phenotypes in mice is always difficult, 
and mouse assays modelling disturbed social functions in humans are highly 
limited. Currently, the most common test is the three-chambered social approach 
paradigm from the lab of J. Crawley (Moy et al., 2004). Unfortunately, this test is 
sensitive to lab-to-lab variability, and results of mouse models for ASD are difficult 
to reproduce (Ey et al., 2012). There is even a study available indicating that 
C57Bl/6J animals fail to show a preference for social novelty in the automated 
three-chamber apparatus (Pearson et al., 2010). As such, we felt the need to 
develop a new social memory task, which considers the rich and complex social 
behavior mice can exhibit. So far, I have worked on a novel test chamber called 
Sociobox, which allows for the presentation of ultimately 10 strangers mice. With 
this version, we are aiming to improve the phenotyping of mouse models of ASD 
and to provide more robust results for potential pharmacological interventions.  
 
Given that cognitive deficits are frequently observed in neurodegenerative 
diseases including autism spectrum disorders, major depression, anxiety 
disorders and schizophrenia, we were also interested in the involvement of the 
endogenous erythropoietin (EPO)-system in various cognitive functions. It is well 
known that erythropoietin stimulates neurogenesis and can ameliorate cognitive 
symptoms in human neuropsychiatric diseases, including schizophrenia, as 
shown previously by our group (Ehrenreich et al., 2007). As such, we addressed 
the application of EPO as a possible treatment option for cognitive decline in 
disease and for cognitive improvement under wildtype conditions in mice. Mouse 
assays for the assessment of higher cognitive functions are anyhow limited, the 
improvement of these functions (e.g. cognitive flexibility) are rather difficult to 
measure with most of the paradigms available. For example in Morris water maze, 
a superior cognitive function is not possible to delineate by the basic paradigm 
protocol used in most of the laboratories, since the swimming speed is limited by 
the muscle capacities of each mouse and can not be further increased. Hence, 
the development of more sophisticated testing tools is mandatory, which will 
enable a more detailed analysis of the learning capacities of each mouse, and 
also allow the revelation of superior performance in higher cognitive functions. 
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Bussey and colleagues have adapted to mice a touchscreen-based operant 
learning paradigm, which is similar to the ones used in humans (Robbins et al., 
1998) and in monkeys (Dias et al., 1996) and allows the assessment of 
sophisticated learning tasks, in which mice learn to respond to a touch-sensitive 
screen (Izquierdo et al., 2006). In this task, reversal learning functions can be 
used as a measure of cognitive flexibility. The subject first learns to associate a 
stimulus with a reward and then the reward contingency is reversed, overall taxing 
multiple executive functions, including attention, working memory and response 
inhibition (Brigman et al., 2010). I was able to establish the touchscreen-based 
visual discrimination and reversal task in our unit. The protocol I am using was 
adapted from Izquierdo and coworkers from 2006 (Izquierdo et al., 2006) and is 
comprised of several phases, starting with reward approach training, touch 




Figure 1 Illustration of the phases necessary for the assessment of visual discrimination and 
its reversal in a touchscreen based operant system (adapted from Brigman et al., 2010) 
 
Since the touchscreen based visual discrimination and reversal paradigm fulfils 
the characteristics of a multifaceted learning task, after the successful 
establishment, we are currently assessing the effect of EPO application in mice on 
the learning performance in the touchscreen paradigm.  
 
It has been described that people with ASD show difficulties in flexibly adjusting 
behavior according to environmental demands, and that these so-called inhibition 
problems are often observed in communication and social interactions. Thus, 
there is a general notion that inhibitory abilities underlie many of the atypical 
behaviors seen in people with ASD (de Vries et al., 2014). Since it is difficult to 
develop tests addressing the same executive functions seen in humans, no 
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studies so far have looked into the inhibition ability of animal models of autism. 
With the touchscreen-based operant system we will also be able to test for 
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